A5048306202- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Chronic Lymphocytic Leukemia Research
- Hemophilia Treatment and Research
- Histone Deacetylase Inhibitors Research
- Venous Thromboembolism Diagnosis and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Retinal Diseases and Treatments
- Retinal Imaging and Analysis
- Pancreatic and Hepatic Oncology Research
- Atrial Fibrillation Management and Outcomes
- Glaucoma and retinal disorders
- Cancer Genomics and Diagnostics
- Energy, Environment, and Transportation Policies
- Acute Myeloid Leukemia Research
- Climate Change Policy and Economics
- Regional Development and Policy
- Retinal and Optic Conditions
- Mass Spectrometry Techniques and Applications
- Transportation Safety and Impact Analysis
- Retinal and Macular Surgery
Bristol-Myers Squibb (United States)
2020-2025
California University of Pennsylvania
2025
Hanken School of Economics
2024
Bayer (United States)
2012-2021
Research Institute of the Finnish Economy
2020
University of Copenhagen
1999-2007
Glostrup Hospital
2007
Herlev Hospital
1999-2005
Abstract Pancreatic ductal adenocarcinoma has a dismal prognosis. A comprehensive analysis of single-cell multi-omic data from matched tumour-infiltrated CD45+ cells and peripheral blood in 12 patients, two published datasets, reveals complex immune infiltrate. Patients have either myeloid-enriched or adaptive-enriched tumour microenvironment. Adaptive cell-enriched is intrinsically linked with highly distinct B T cell clonal selection, diversification, differentiation. Using TCR data, we...
Durable responses with lenalidomide monotherapy have been reported in patients non-Hodgkin lymphoma. In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), higher were observed the activated B-cell-like (ABC) subtype than germinal centre subtype. Herein, molecular mechanisms involved differential efficacy of DLBCL subtypes investigated. Using cell lines, treatment was found to preferentially suppress proliferation ABC-DLBCL cells vitro and delay tumour growth a human xenograft model,...
The phase III EINSTEIN DVT and PE trials demonstrated the potential of oral rivaroxaban for treatment deep vein thrombosis (DVT) pulmonary embolism (PE). length initial hospitalization in patients presenting with either symptomatic or was assessed using records from these trials.Analyses were carried out intention-to-treat population, non-parametric parametric statistical methods.Overall, 52% (1781/3434) 90% (4328/4821) admitted to hospital. proportion hospitalized a stay five fewer days...
The EU Emission Trading System (EU ETS) has been shown to have reduced emissions in the participating countries and industries since its adoption 2005. However, there is less evidence on shifting of production outside avoid emission controls. We study this so-called carbon leakage with gravity analysis international trade flows intensities trade. utilize model a sectoral level implications empirically. Our findings new OECD data indicate that some fact occurred due ETS, resulting higher...
Summary Cereblon, a member of the cullin 4 ring ligase complex ( CRL 4), is molecular target immunomodulatory drugs IM i D s) lenalidomide and pomalidomide required for antiproliferative activity these agents in multiple myeloma MM ) T cells. Cereblon's central role as suggests potential utility predictive biomarker response or resistance to therapy. Our studies characterized cereblon monoclonal antibody CRBN 65, with high sensitivity specificity W estern analysis immunohistochemistry that...
With the explosion of immuno-oncology and approval many immune checkpoint therapies by regulatory agencies in last few years, understanding tumor microenvironment (TME) context patients' status has become essential. Among available profiling techniques, multiplex immunofluorescence (mIF) assays offer unique advantage preserving architectural features revealing spatial relationships between cells cells. A number mIF image analysis have been described for solid tumors but most are not...
Abstract. Purpose: To describe abnormal subretinal material in central serous chorioretinopathy (CSC). Design: Retrospective observational case series. Participants: 168 consecutive patients (336 eyes) with a definite diagnosis of foveal detachment attributable to CSC one or both eyes, on more occasions. Methods: Review all cases seen during six‐year period. Grading the amount at presentation as absent, questionable, mild, moderate severe. Results: Of CSC, 133 (79%) were men and 35 (21%)...
Objective:Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [(PE]) represents a substantial economic burden to the healthcare system. Using data from randomized EINSTEIN DVT PE trials, this North American sub-group analysis investigated potential of rivaroxaban reduce length initial hospitalization in patients with acute symptomatic or PE.Methods:A post-hoc length-of-stay (LOS) was conducted sub-set randomized, open-label trial program. Patients received either...
Summary Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma ( MCL ); however, despite this observed activity, the mechanism of action MOA ) lenalidomide not been characterized in setting. We investigated samples from enrolled CC ‐5013‐ ‐002 trial NCT 00875667) comparing single‐agent versus investigator's choice therapy and validated our findings pre‐clinical models . Our results revealed a significant...
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled CC-220-MM-001 (ClinicalTrials.gov: NCT02773030), phase 1/2 study, shows that iberdomide treatment induces significant target substrate degradation tumors, including immunomodulatory (IMiD)-refractory or those with low CRBN levels. Additionally, some genetic dysregulation who responded to have similar...
The Calcium Homeostasis Modulator (CALHM) proteins comprise a family of six genes, some which have been demonstrated to function as ion channels. CALHM1, the founding member, is an extracellular Ca 2+ - and voltage-gated large-pore non-selective channel. mechanisms by voltage regulate CALHM1 channel gating are unknown. Cryo-electron microscopic structures its paralogs provided little insights into these features, although they suggested that amino-termini, including amino-terminal helix...
To study the evening-to-morning variation in retinal thickness patients with fovea-involving diabetic macular edema.Twelve eyes 12 aged 39 to 78 years (mean, 57) edema and 14 7 healthy volunteers 30 70 were examined by optical coherence tomography, evening morning after > or =6 hours of sleep recumbent position darkness followed 0.5 hour wakefulness same room light both open.In edema, increased overnight, from 316 +/- 72 microm 336 81 (P = 0.003). Visual acuity decreased a mean 41 ETDRS...
Abstract Introduction BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with for 36 weeks. Aim To report long‐term and safety in a descriptive analysis the ongoing extension total treatment time up to >5 years. Methods Previously treated males aged 12‐65 years severe haemophilia A who completed were eligible open‐label...
Abstract Introduction The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi ® ), a B‐domain‐deleted recombinant factor (FVIII), site‐specifically PEGylated to extend its half‐life. Aim To report the final data for from extension. Methods Previously treated males aged 12–65 years with severe haemophilia A (FVIII <1%) who completed multicentre, open‐label were eligible Patients received either on demand or prophylaxis treatments...
In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have direct anti-MM effect and in vitro synergism when combined with lenalidomide (LEN). We present phase 1b, single center, 3 × dose escalation study planned expansion at maximum tolerated (MTD), which assessed the safety efficacy of combining CC-486 LEN (25 mg d1-21/28) dexamethasone (DEX) (40 weekly) patients relapsed/refractory MM who had previously failed LEN. Twenty-four were enrolled. The MTD...